EP1126788B1 - Systeme pour l'imagerie radiographique des tissus - Google Patents

Systeme pour l'imagerie radiographique des tissus Download PDF

Info

Publication number
EP1126788B1
EP1126788B1 EP99945495A EP99945495A EP1126788B1 EP 1126788 B1 EP1126788 B1 EP 1126788B1 EP 99945495 A EP99945495 A EP 99945495A EP 99945495 A EP99945495 A EP 99945495A EP 1126788 B1 EP1126788 B1 EP 1126788B1
Authority
EP
European Patent Office
Prior art keywords
tissue
image
moiety
imaging agent
imaging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP99945495A
Other languages
German (de)
English (en)
Other versions
EP1126788A2 (fr
Inventor
Jesse Salb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Veritas Pharmaceuticals Inc
Original Assignee
Veritas Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veritas Pharmaceuticals Inc filed Critical Veritas Pharmaceuticals Inc
Publication of EP1126788A2 publication Critical patent/EP1126788A2/fr
Application granted granted Critical
Publication of EP1126788B1 publication Critical patent/EP1126788B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/48—Diagnostic techniques
    • A61B6/482—Diagnostic techniques involving multiple energy imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/40—Arrangements for generating radiation specially adapted for radiation diagnosis
    • A61B6/4035—Arrangements for generating radiation specially adapted for radiation diagnosis the source being combined with a filter or grating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/40—Arrangements for generating radiation specially adapted for radiation diagnosis
    • A61B6/4035—Arrangements for generating radiation specially adapted for radiation diagnosis the source being combined with a filter or grating
    • A61B6/4042—K-edge filters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/42—Arrangements for detecting radiation specially adapted for radiation diagnosis
    • A61B6/4208—Arrangements for detecting radiation specially adapted for radiation diagnosis characterised by using a particular type of detector
    • A61B6/4241—Arrangements for detecting radiation specially adapted for radiation diagnosis characterised by using a particular type of detector using energy resolving detectors, e.g. photon counting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/032—Transmission computed tomography [CT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/40—Arrangements for generating radiation specially adapted for radiation diagnosis
    • A61B6/4064—Arrangements for generating radiation specially adapted for radiation diagnosis specially adapted for producing a particular type of beam
    • A61B6/4092—Arrangements for generating radiation specially adapted for radiation diagnosis specially adapted for producing a particular type of beam for producing synchrotron radiation

Definitions

  • This invention relates to medical imaging and specifically to a system and imaging agent for localization of certain types of abnormal tissue, such as malignant tissue, using radiography.
  • Radiography involves examination of internal organs of the body by transillumination with X-rays.
  • the image receptor may be radiographic film, a film/intensifying screen combination, a stimulable phosphor storage plate, a fluoroscopic image intensifier, an amorphous silicon sensor array, a CCD/scintillator combination, or another type of X-ray sensitive receptor.
  • a computer digitizes the acquired image and may enhance it using image processing algorithms.
  • the most commonly performed radiographic procedures include mammography, in which images of the breast are generated to detect breast cancer, and thoracic radiography, in which images of the lungs and heart are generated to detect a variety of diseases, including lung cancer.
  • a major goal of radiography is the reliable detection of malignant tissue and its accurate differentiation from non-malignant tissue.
  • the radiologist decides whether tissue is malignant, benign or normal solely by visual inspection of the radiograph.
  • the appearance of tissue on a radiograph mainly depends on the degree to which the transilluminating X-ray beam is attenuated during its traversal of the different areas of the tissue being examined.
  • it has been repeatedly demonstrated that the visual appearance of tissue on the radiograph is not a reliable criterion for definitive diagnosis of malignancy.
  • a false positive also called an error in specificity, occurs when a radiograph is judged to display malignant tissue that ultimately proves benign.
  • a false negative also called an error in sensitivity, occurs when malignant tissue actually present is not detected on the radiograph.
  • mammography In which the breasts are examined for evidence of cancer. Approximately 25 million primary screening mammograms are performed annually in the United States. However, the high incidence of false positives and false negatives reduces the reliability of mammography as a diagnostic tool.
  • cysts and fibroadenomas are benign fluid-filled tissue structures that may often be present in an otherwise normal breast.
  • Fibroadenomas are benign growths of tissue that may also be present in a normal breast. Both types of structures may feel lumpy during palpation by the patient or a physician, and may thus resemble malignant tumors in a physical examination.
  • cysts and fibroadenomas appear as areas of decreased radiographic density on mammograms. Their radiographic appearance can closely resemble that of malignant tumors, which also appear as areas of decreased density.
  • a more serious problem in diagnostic mammography is the high incidence of false negatives, in which malignant tumors that are actually present are not detected on the mammogram. Missed tumors may be detected months or years later on a subsequent mammogram or by palpation. During this interval the tumor may grow larger and, in the worst case, metastasize.
  • Various published studies on diagnostic accuracy in mammography report a false negative rate of between 8% and 24% [ van Dijck JA et al.: Cancer 72: 1933-1938 (1993 ); Bird RE et al.: Radiol. 184: 613-617 (1992 ); Wallis MG et al.: Clin. Radiol. 44: 13-15 (1991 )].
  • malignant tumors may not be noticed even upon careful inspection of the mammogram by an experienced radiologist. Tumors may be too small to be detected, or their appearance may be obscured by benign tumors or cysts. The visibility of malignant tumors may be further obscured in younger women, whose breast tissue is often dense. As a consequence, the rate of false negatives in these women is even higher than in the general population.
  • an improved method for visualization of small malignant tumors on mammograms would enable their earlier detection, enhance the effectiveness of therapy, and prolong patient survival time.
  • an improved method for differentiation of malignant tissue from benign and normal tissue on thoracic radiographs would reduce the large number of unnecessary follow-up procedures currently performed, decreasing cost and morbidity.
  • an improved method for visualization of small malignant lung tumors on thoracic radiographs would enable earlier detection of these tumors and prolong patient survival time.
  • Radiographs with higher spatial resolution improve the ability of the radiologist to visualize fine anatomical detail.
  • this approach is fundamentally flawed because detection of malignant tissue, even in high-resolution images, still largely depends on variations in radiographic density. But, as previously noted, radiographic density alone is not a reliable criterion for detection of malignant tissue. Improved spatial resolution can therefore result in only a modest improvement in diagnostic accuracy.
  • PET functional imaging exploits the fact that the glucose metabolic rate of malignant tissue is considerably elevated relative to that of benign and normal tissue in the same organ.
  • a positron-emitting radioactive glucose analog typically 18 F-2-fluoro-2-deoxyglucose, is administered to the patient. After an interval of approximately one hour, images of the distribution of the radioactive glucose analog in body tissue are acquired by a photon detector array that surrounds the patient.
  • PET PET-relatively low spatial resolution is a limitation common to imaging modalities that depend on detector arrays for the measurement of high-energy particles emitted from radiopharmaceuticals. Because of its low spatial resolution, PET exhibits a high rate of false negatives in the detection of small malignant tumors.
  • a third disadvantage of PET is the length of the imaging procedure.
  • the time required for a patient to be immobile during a PET scan may be one-half to one hour, while radiographic images can be acquired in a few minutes.
  • SPECT single-photon emission computed tomography
  • Tc-99m-Sestamibi The most common radiopharmaceutical used in SPECT imaging of malignant tissue is Tc-99m-Sestamibi. Results of a number of studies have shown selective uptake of Tc-99m-Sestamibi in malignant tumors of various types.
  • SPECT imaging has limitations that reduce its utility in the diagnosis of malignant tumors.
  • a major limitation of the technique is the low spatial resolution of the images, which results in a sharp decrease in sensitivity for breast tumors smaller than 1.5 cm.
  • a second disadvantage of SPECT in breast cancer imaging is the relatively low specificity.
  • Tc-99m-Sestamibi produces a significant number of false positives in patients with benign fibroadenomas. Since fibroadenomas constitute the most frequent source of false positives, and frequently result in unnecessary biopsies, the large number of false positives produced by Tc-99m-Sestamibi reduces its value in breast cancer imaging.
  • SPECT In diagnostic imaging of the lung, SPECT generates false positives in conditions such as tuberculosis, pneumonia, and granulomas. It is thus inadequate for the reliable diagnosis of lung cancer.
  • CT computed tomography
  • MRI magnetic resonance imaging
  • ultrasound ultrasound
  • US 4,887,604 discloses an energy subtraction medical imaging system which is used for imaging a body part impregnated with a radio-opaque dye such as iodine.
  • US 4,455,292 discloses a radiological contrast composition for cerebrospinal myelography combining an iodo-benzamido-glycopyranose contrast agent and glucose.
  • US 4,716,225 discloses a method of metabolically mapping one or more central nervous system components of a mammalian body by computerized axial tomography scanning which entails injecting an effective amount of a 2-, 5- or 6-iodo-substituted hexose, as a contrast medium, into the mammalian body, and scanning the mammalian body by computerized axial tomography, thereby visualizing the concentration flux of said hexose in the central nervous system component or components.
  • contrast agents have also developed to enhance the delineation of tissue on radiographic images [ Torsten et al.: U.S. Pat. No. 3,701,771 ; Speck et al.: U.S. Pat. No. 4,364,921 ; Nordal et al.: U.S. Pat. No. 4,250,113 ; Sovak et al.: U.S. Pat. No. 4,243,653 ].
  • radiographic contrast agents function by passively outlining body organs and structures, thereby enhancing anatomical contrast on the radiograph. These imaging agents generally accumulate in the extracellular space.
  • radiographic contrast agents are hydrophilic, and are therefore not cell-membrane permeable [ Speck U: Contrast Media pp. 1-23. Churchill Livingstone, New York (1988 )]. Studies of tissue distribution at the cellular level confirm that commonly used radiographic contrast agents, such as metrizamide, iohexol, and meglumine calcium metrizoate, do not permeate the cell membrane nor enter the intracellular cytosol.
  • Golman K Acta Radiol. Suppl. S335: 300-311 (1973 ); Ekholm SE et al.: Acta Radiol. [Diagn] (Stockh) 26: 331-336 (1985 ); Gjedde A: Acta Neurol. Scandinav.
  • contrast agent molecules are not cell membrane-permeable, they cannot exit the vesicles which enclose them. They therefore have no direct access to the cytosol, and consequently do not specifically interact with, or bind to, intracellular targets.
  • Similar contrast agents have been designed to enhance radiographic images of the liver by entering hepatocytes.
  • molecules of these contrast agents are physically localized within the cell, but are compartmentalized within liposomes or intracellular vesicles. They are thus separated from the cytosol by the membrane barrier surrounding the liposome or vesicle. Since the molecules are not membrane-permeable, they do not have direct access to the cytosol and do not specifically interact with intracellular targets.
  • Ledley and Gersten (U.S. Pat. No. 4,716,225 ) disclosed a method of metabolic mapping of the central nervous system using iodinated sugar derivatives.
  • the sugar derivatives are hexoses substituted with iodine atoms in either the C-2, C-5, or C-6 positions.
  • Patterns of metabolism are mapped using CT scans to generate images of the concentration flux of the radio-opaque sugars in different areas of tissue in the central nervous system.
  • the concentration flux is a measurement which reflects the rate of uptake of the compounds by cells.
  • the disclosed radio-opaque sugar derivatives are hydrophilic, and enter cells only via facilitated transport by the glucose transport (GLUT) proteins. Because the radio-opaque sugar derivatives are iodine-substituted in different ring positions, their interaction with the GLUT proteins differ from the interaction of native hexoses with these proteins. The binding requirements of the GLUT proteins are asymmetrical, and depend on which side of the cell membrane the sugar ligand is located. [ Mueckler M: Eur. J. Biochem. 219: 713-725 (1994 ); Barnett JEG et al.: Biochem. J. 131: 211-221 (1973 ); Barnett JEG et al.: Biochem. J.
  • radiographic imaging agent that facilitated generation of functional physiological images in addition to the anatomical images now provided by radiographs, and which could be used with widely available radiographic imaging devices, would be of great value in the practice of radiography, particularly in the diagnostic imaging of cancer. This capability is not currently provided by any radiographic contrast agent.
  • the simultaneous display of functional images and anatomical images of high resolution, with both images superimposed in registration is highly desirable for diagnostic and research purposes in medical imaging.
  • Registration refers to the exact visual alignment, or superimposition, of two or more images from the user's viewpoint.
  • the capability of interactively varying the proportions of the displayed functional and anatomical information on a single image with complete registration would also be of great value. With this capability, for example, areas of abnormal functional (physiological) activity might be correlated with nearby anatomical landmarks, and either the anatomical or functional image might be emphasized. These capabilities would enhance the ability of the physician to precisely localize areas of abnormal tissue such as malignant tumors. These capabilities are not provided by any currently available single imaging modality.
  • Wang U.S. Pat. No. 5,729,620 ) disclosed a system for superimposing digitized images representing X-ray data in registration with an annotation map.
  • the annotation map may be constructed by a computer-aided diagnosis (CAD) system.
  • CAD computer-aided diagnosis
  • the invention does not suggest a method of superimposing anatomical images in registration with functional (physiological) images of tissue, as CAD systems do not provide functional images.
  • An ideal imaging modality should combine the proven diagnostic accuracy of functional imaging of tissue physiology with the high anatomical resolution of radiography. It may also provide the ability to display functional and anatomical information on a single image with complete registration. An imaging modality with these characteristics should improve detection of small tumors at an earlier stage in their development, and improve differentiation of malignant from non-malignant tissue. Both false negative and false positive errors should thereby be reduced. The diagnostic imaging of other types of abnormal tissue should also be improved.
  • the ideal imaging modality should also provide low-cost images, improve the accuracy of currently installed radiographic imaging devices, and not require the use of radiopharmaceuticals. An imaging modality providing these advantages should satisfy an urgent need in the practice of diagnostic imaging.
  • the present invention is a system and an imaging agent for improved detection and localization of abnormal or diseased tissue, such as malignant tissue, using radiography.
  • the capability of generating a radiographic image of tissue that combines both functional (physiological) and anatomical information on a single image with the two types of information in complete spatial registration are described.
  • the method described also allows the viewer to interactively control the relative proportions of functional and anatomical information presented on the displayed image. This capability facilitates the precise localization of certain types of tissue, such as functionally abnormal malignant tissue, in relation to anatomical structures.
  • the present invention will be particularly useful in mammography and thoracic radiography, imaging modalities that currently demonstrate high error rates of diagnostic sensitivity and specificity. However, it can also improve the accuracy of a broad range of radiographic imaging procedures used for detection of abnormal or diseased tissue.
  • the present invention is a system for radiographic imaging of body tissue as defined in claim 1.
  • This system may be used in a method described herein comprising:
  • Another method described herein includes:
  • the X-ray beams used in this method may be quasi-monoenergetic or monoenergetic.
  • the method may further include displaying variable proportions of radiographic density contributed by the imaging agent, by soft tissue, and by bone to the displayed image.
  • the cell membrane-permeable, radio-opaque imaging agent may selectively bind, either covalently or non-covalently, to a cellular target.
  • the cellular target may be a cellular structure, such as an organelle, or a cellular molecule.
  • the cellular target may be an enzyme, a non-enzyme protein, a coenzyme, a nucleic acid, or a lipid.
  • the cellular target may be hexokinase.
  • the imaging agent may accumulate in malignant tissue at a different rate than in nonmalignant tissue.
  • the imaging agent may accumulate in abnormal myocardial tissue at a different rate than in normal myocardial tissue.
  • Also described is a method for generating a functional image and an anatomical image of tissue in registration comprising:
  • the radio-opaque imaging agent may comprise a cell membrane- permeable composition having a general formula S-L-X, wherein:
  • the invention relates to a composition as defined in claim 19.
  • the invention is based on the wellestablished principle that malignant tissue may be reliably distinguished from benign and normal tissue by its characteristically elevated rate of glucose metabolism. Specifically, almost all types of malignant tissue metabolize glucose at a considerably higher rates than benign and normal tissue of the same body organ. It has also been established that malignant tissue contains elevated levels of a number of the enzymes active in glucose metabolism.
  • Hexokinase is an enzyme which is particularly overexpressed in malignant cells. Hexokinase catalyzes the first step in glucose metabolism, which is the phosphorylation of glucose to glucose-6-phosphate. Quantitative studies have consistently demonstrated elevated levels of hexokinase in malignant tissue, with the increased enzyme level approximately proportional to the increased tissue glucose metabolic rate. Hexokinase is therefore an appropriate target enzyme for detection and localization of malignant tissue.
  • one method described herein utilizes a functional imaging agent which comprises a cell membrane-permeable, radioopaque, high-affinity ligand for intracellular hexokinase.
  • a hexokinase substrate or inhibitor is linked to a non-radioactive, radioopaque moiety in a manner that facilitates efficient passage of the imaging agent across the outer cell membrane (plasma membrane), direct entry into the cytosol, and selective binding with high affinity to the substrate binding site of intracellular hexokinase molecules.
  • the cell membrane-permeable property of the imaging agent molecules insures their direct entry into the cytosol, and the exit of unbound imaging agent molecules across the cell membrane.
  • imaging agent molecules that have bound to hexokinase are retained within the cell for at least a few hours. Unbound imaging agent molecules exit the cell at a relatively rapid rate, decreasing background radio-opacity and increasing contrast in the radiographic image. Because of the much higher concentration of hexokinase in malignant cells relative to benign and normal cells, the imaging agent accumulates in malignant tissue at an elevated level relative to benign and normal tissue.
  • a radiographic procedure is initiated by administering the imaging agent to a live patient. After the imaging agent accumulates throughout body tissue during a predetermined interval, the patient is appropriately positioned in relation to the X-ray source and image receptor, and radiographic images are acquired. Tissue that metabolizes glucose at a high rate, particularly malignant tissue, will have accumulated higher intracellular levels of the imaging agent than tissue that metabolizes glucose at a lower rate, such as benign and normal tissue. Because the imaging agent is radio-opaque, its differential accumulation causes corresponding differences in the absorption of the illuminating X-ray beam, which are manifested as differing levels of radiographic density on the radiograph.
  • radiographic density contributed by the accumulated imaging agent is isolated from radiographic density contributed by soft tissue and bone.
  • the tissue being examined is sequentially transilluminated by X-ray beams with predetermined different mean energy spectra, and a separate radiographic image is acquired during transillumination by each beam.
  • the image processing system uses a predetermined weighting coefficient for each image, the image processing system performs a weighted combination of the acquired images to produce a single displayed image.
  • the remaining radiographic density present on the displayed image is contributed solely by differential intracellular accumulation of the radio-opaque imaging agent in malignant, benign, and normal tissue.
  • this image of accumulated imaging agent is a functional image of tissue physiology, it is displayed with the high spatial resolution of a radiographic image.
  • the viewer may interactively vary the proportion of radiographic density contributed to the displayed image by accumulated imaging agent, by soft tissue, and by bone.
  • a functional image of tissue combined with a variable degree of a superimposed anatomical image in registration may thereby be displayed.
  • the combination of functional and anatomical information on a single image, or, if desired, on a series of images, facilitates the precise localization of malignant tissue in relation to nearby anatomical landmarks.
  • Advantages of the method described herein include enhanced visibility of small areas of functionally abnormal tissue on the radiographic image, and improved differentiation of malignant tissue from benign tissue of increased radio-opacity.
  • benign tissue of increased radio-opacity include cysts and fibroadenomas in the breast, and granulomas in the lung.
  • cysts and fibroadenomas are the major sources of false positives in mammography, their rate of glucose metabolism is not elevated relative to that of normal tissue.
  • the rate of glucose metabolism in granulomas which are a major source of false positives in thoracic radiography, is likewise not elevated.
  • the invention may be used for imaging particular body organs such as the breast, lungs, liver and colon, in single or multiple images, or for imaging large areas of the body or the whole body in single or multiple images.
  • the present invention may be used in computed tomography and other radiographic modalities, as well as in standard radiographic imaging methods such as mammography and thoracic radiography.
  • the method described herein is thus capable of generating images that combine the diagnostic accuracy provided by functional imaging of tissue physiology with the high anatomical detail and spatial resolution provided by radiography.
  • a radiographic imaging agent should enhance the signal-to-noise ratio of abnormal or diseased tissue relative to normal tissue in the radiographic image.
  • bidirectionally cell membrane-permeable radio-opaque imaging agents rapidly enter cells and selectively bind to cellular targets whose concentrations or activity is significantly different in abnormal or diseased tissue than in normal tissue. Accumulation levels of the imaging agents are therefore different in abnormal tissue than in normal tissue.
  • the imaging agents also efficiently exit cells so that the intracellular concentration of unbound or unincorporated imaging agent decreases to a sufficiently low residual level to diminish background noise and enhance contrast on the radiographic image.
  • Hexokinase catalyzes the first step in glucose metabolism, which is the phosphorylation of glucose to glucose-6-phosphate.
  • Malignant cells markedly overexpress hexokinase relative to benign and normal cells from the same organ [ Weber G: Gann Monogr. Cancer Res. 13: 47-77 (1972 ); Weinhouse S: Cancer Res. 32: 2007-2016 ].
  • a portion of intracellular hexokinase is located in the cytosol in soluble form, and another portion is located in the cytosol and attached to the outer mitochondrial membrane [ Arora KK, Pedersen PL: J.
  • hexokinase activity of normal, benign and malignant tissue is roughly proportional to their respective rates of glucose metabolism.
  • Kinetic analysis of the k compartments in PET glucose imaging studies indicates that the increase in glucose metabolic rate in malignant tissue can largely be accounted for by increased activity of hexokinase in the k 3 (phosphorylation) compartment.
  • the detection and quantitation of hexokinase is thus a particularly useful method for identification of malignant tissue.
  • one embodiment of the radio-opaque functional imaging agent of the present invention is a cell membrane-permeable, high-affinity ligand for intracellular hexokinase.
  • a hexokinase substrate or inhibitor is linked to a non-radioactive, radio-opaque moiety in a manner that permits efficient diffusion of the imaging agent across the cell membrane into the cytosol and attachment with high affinity to the substrate binding site of intracellular hexokinase molecules.
  • the molecule may comprise an amino sugar, in pyranose or furanose form, attached by means of a covalent linkage arm to a moiety containing one or more atoms of a radio-opaque element, which may be iodine.
  • One function is to minimize steric hindrance of the substrate binding site by the radio-opaque moiety of the imaging agent.
  • the second function is to enhance binding of the imaging agent molecule to the enzyme through beneficial interactions, including hydrogen bonds and van der Waals contacts, with amino acid residues in the vicinity of the binding site.
  • the chain length of the linkage arm separating the pyranose or furanose ring from the radio-opaque moiety should be a minimum of approximately 8 ⁇ . Shorter chain lengths may allow unwanted interactions between the radio-opaque moiety and residues local to the substrate binding site. Longer chain lengths may produce unwanted non-specific interactions with other intracellular components, although longer chain lengths may be used with the present invention.
  • substituents may be inserted into the linkage arm to further improve the binding affinity of the imaging agent for the enzyme.
  • a particularly effective linkage arm is comprised of a benzoic acid moiety containing a polar substituent, such as a nitro- or amino- group, in the ortho or meta position.
  • substituent characteristics should be carefully controlled. For example, substituent bulk above a certain size may result in steric hindrance and a sharp decrease in binding affinity.
  • the imaging agent of one embodiment should readily permeate the cell membrane and enter the cytosol in order to bind intracellular enzyme molecules. Further, imaging agent molecules which have not attached to enzyme molecules should efficiently exit the cell to effectively reduce background radio-opacity.
  • Glucose is normally transported bidirectionally across the cell membrane by means of one or more of the GLUT transport proteins. Substituents in, or moieties linked to, the basic pyranose or furanose ring can inhibit transport by these proteins. Design of the imaging agent so that it is lipophilic insures its efficient bi-directional diffusion across the cell membrane, without the necessity for facilitated transport by the GLUT proteins.
  • lipophilicity of imaging agents was characterized by computed logP.
  • Lipophilicity is defined as the partitioning of a compound between an aqueous and a nonaqueous phase, with the nonaqueous phase usually chosen to be n-Octanol.
  • LogP is the log of the partition coefficient of a compound between the two phases, and is a standard measure of lipophilicity in biological systems. For a wide range of small non-ionic molecules, strong correlations have been experimentally verified between logP and the distribution of the molecule between the aqueous medium and the cell membrane [ Hansch et al.: J. Pharm Sci. 61: 1-19 (1972 )].
  • Table 1 shows experimental logP values and molecular weights of some commonly used non-ionic radiographic contrast agents [ Hansch et al: Exploring QSAR, Amer. Chem Soc., Washington DC (1995 )].
  • the table also shows computed logP values and molecular weights of glucose and of representative iodo-substituted hexose imaging agents disclosed by Ledley and Gersten ( U.S. Pat. No. 4,716,225 ).
  • the computed logP values and molecular weights of Examples 1-3 of the present invention are also shown.
  • TABLE 1 Compound logP MW U.S. Pat.
  • the molecular weights of the compounds in Table 1 are all below 1000 daltons.
  • the logP values of the first three contrast agents are below 0.0, and are consistent with their demonstrated hydrophilicity and inability to permeate cell membranes.
  • the logP values of all iodo-substituted hexose compounds disclosed by Ledley and Gersten, two representative examples of which are listed in Table 1, are also below 0.0.
  • Examples 1-3 of the present invention have logP values above 0.0, and their relatively high lipophilicity enhances their passive diffusion across the cell membrane and entry into the cytosol.
  • the radio-opaque moiety of the imaging agent contains one or more atoms of an element, which may be iodine, which exhibits suitable radio-opacity in the photon energy spectrum emitted by a typical diagnostic X-ray source operated at approximately 50 keV to approximately 80 keV.
  • an element which may be iodine, which exhibits suitable radio-opacity in the photon energy spectrum emitted by a typical diagnostic X-ray source operated at approximately 50 keV to approximately 80 keV.
  • iodine is the most common radio-opaque element used for enhancement of radiographic contrast
  • other selected elements may be used in the radio-opaque moiety in alternate embodiments of the imaging agent.
  • the suitability of an element for use in the radio-opaque moiety will depend on the photon energy of the element's K-absorption edge, a property explained in detail in section E.
  • Radio-opaque elements with higher K-absorption edges may generally be used with X-ray beams of higher photon energy, and elements with lower K-absorption edges may generally be used with X-ray beams of lower photon energy.
  • radio-opaque imaging agent The general form of one embodiment of the radio-opaque imaging agent is wherein:
  • Functionalized groups including hydrophilic groups containing one or more hydroxyls or carbamoyls, may be also optionally be substituted at one or more positions of the X moiety to shield the radio-opacifying atom or atoms from causing chemotoxic responses in vivo.
  • the S moiety is a pyranose or furanose that attaches to the binding site of an intracellular enzyme;
  • the X moiety is radio-opaque in the portion of the energy spectrum typically used in diagnostic radiographic imaging; and the L moiety is bonded to the S moiety and to the X moiety.
  • the L moiety positions the X moiety at a sufficient distance from the pyranose or furanose ring to prevent steric hindrance of the binding site, and enhances affinity of the molecule for the enzyme through hydrogen bonds and Van der Waals interactions with residues in the vicinity of the substrate binding site, and amide-amide interactions with the protein backbone.
  • 4-iodotoluene is reacted with picryl chloride in the presence of copper bronze at 215° C to yield 2',4',6'-trinitro-4-methylbiphenyl (1).
  • 2',4',6'-trinitro-4-methylbiphenyl (1) is reacted with stannous chloride and hydrochloric acid to yield 2',4',6'-triamino-4-methylbiphenyl (2).
  • 2',4',6'-triamino-4-methylbiphenyl (2) is reacted with sodium nitrite and hydrochloric acid to convert the amino groups to diazonium groups.
  • the diazonium groups react with potassium iodide to yield 2',4',6'-triiodo-4-methylbiphenyl (3).
  • Aromatic nitration of 2',4',6'-triiodo-4-methylbiphenyl (3) is performed with nitric acid and sulfuric acid to yield a mixture of 2',4',6'-triiodo-2-nitro-4-methylbiphenyl (4) and 2',4',6'-triiodo-3-nitro-4-methylbiphenyl (5).
  • the products are separated using column chromatography.
  • the methyl group of 2',4',6'-triiodo-3-nitro-4-methylbiphenyl (5) is oxidized by potassium permanganate to yield 2',4',6'-triiodo-3-nitrobiphenyl-4-carboxylic acid (6).
  • 2',4',6'-triiodo-3-nitrobiphenyl-4-carboxylic acid (6) is reacted with thionyl chloride to yield 2',4',6'-triiodo-3-nitrobiphenyl-4-carbonyl chloride (7).
  • Example 1 2-Deoxy-D-glucose is 2-hydroxy-substituted with a o-aminobenzamide linkage arm, which links the pyranose to a tri-iodophenyl moiety.
  • the pyranose ring binds to the substrate binding site of hexokinase.
  • the o-aminobenzamide linkage arm enhances the binding of the pyranose to the binding site, and also spaces the radio-opaque tri-iodophenyl moiety a sufficient distance from the pyranose to prevent steric hindrance of the binding site.
  • the triiodophenyl configuration provides strong carbon-iodine bonds and thereby insures resistance to deiodination in vivo. Lipophilicity enhances bidirectional diffusion of the molecule across the cell membrane, and is contributed by both the linkage arm and the radio-opaque moiety.
  • the computed logP of Example 1 is 4.64.
  • 2',4',6'-triiodo-3'-acetyl-3-nitrobiphenyl-4-carboxylic acid (12) is then reacted with a zinc mercury amalgam and hydrochloric acid and heated to yield 2',4',6'-triiodo-3'-ethyl-3-nitrobiphenyl-4-carboxylic acid (13).
  • 2',4',6'-triiodo-3'-ethyl-3-nitrobiphenyl-4-carboxylic acid (13) is reacted with thionyl chloride to yield 2',4',6'-triiodo-3'-ethyl-3-nitrobiphenyl-4-carbonyl chloride (14).
  • 1,3,4,6-tetra-O-acetyl-D-glucosamine (9) is reacted with 2',4',6'-triiodo-3'-ethyl-3-nitrobiphenyl-4-carbonyl chloride (14) to yield 2-nitro-4-(3'-ethyl-2',4',6'-triiodophenyl)-benzoyl-1,3,4,6-tetra-O-acetyl-D-glucosamine (15).
  • Example 2 is similar in general structure to Example 1, with the additional presence of a short alkyl chain attached to the radio-opaque tri-iodophenyl moiety at the C-3' position to further increase lipophilicity of the molecule and enhance cell membrane permeability.
  • the computed logP of Example 2 is 5.31.
  • 1,3,4,6-tetra-O-acetyl-D-glucosamine (9) is reacted with 2',4',6'-triiodo-3'5'-bis(ethyl)-3-nitrobiphenyl-4-carbonyl chloride (19) to yield 2-nitro-4-[3',5'-bis(ethyl)-2',4',6'-triiodophenyl]-benzoyl-1,3,4,6-tetra-O-acetyl-D-glucosamine (20).
  • Example 3 is similar in overall structure to Example 1, with the addition of hydrophilic groups added at positions C-3' and C-5' of the radio-opaque aromatic ring to help shield the iodine atoms from causing chemotoxic effects in vivo.
  • the computed logP of Example 3 is 2.65.
  • hydrophilic groups containing one or more hydroxyls or carbamoyls may be also optionally be substituted at the 3' and 5' positions to help shield the iodine atoms from causing chemotoxic responses in vivo.
  • imaging agents for other target enzymes may be synthesized by combining a substrate or inhibitor of the enzyme with a radio-opaque moiety in a manner that permits diffusion of the imaging agent across cell membranes and selective binding to the target enzyme.
  • Imaging agents of this general form may be used for the radiographic detection of a wide variety of normal and abnormal enzymes expressed at varying levels in normal and abnormal body tissue.
  • In situ hybridization is a technique for detection of specific DNA or RNA sequences within cells.
  • the technique may be implemented with an oligonucleotide consisting of a single stranded, predefined sequence of nucleotides which is complementary to a selected nucleotide sequence in an intracellular target DNA or RNA molecule.
  • Such oligonucleotides are generally obtained by chemical synthesis or by enzymatic polymerization.
  • Singer et al. U.S. Pat. No. 5,728,527
  • oligonucleotides were labeled with a fluorophore or with a radioactive isotope.
  • Cells were incubated in the presence of labeled oligonucleotide for a predetermined amount of time to allow the oligonucleotide to enter cells and to hybridize with intracellular target molecules.
  • the cells were then washed to remove unhybridized oligonucleotides.
  • the intracellular level of remaining hybridized oligonucleotides was then determined by measurement of fluorescence or radioactivity.
  • Oligonucleotides have typically been synthesized with the native phosphodiester internucleotide linkages. It has been shown that phosphodiester-bonded oligonucleotides enter cells by means of receptor-mediated endocytosis [ Loke SL et al.: Proc. Natl. Acad. Sci. USA 86: 3474-3478 (1989 )]. In this mode of cellular entry, oligonucleotides molecules attach to receptors on the cell surface and are internalized into the cell through pinching off of the cell membrane to form intracellular vesicles. Although the oligonucleotides are physically localized within the cell, they are separated from the cytosol by the membrane surrounding the vesicles. They therefore do not have direct access to the cytosol, and because of this presumably interact with intracellular RNA and DNA molecules at a relatively inefficient rate.
  • the requirements for a functional radiographic imaging agent for imaging of target DNA and RNA sequences in vivo should include the use of an oligonucleotide sequence complementary to a target intracellular nucleic acid sequence.
  • the imaging agent should be able to bidirectionally permeate the cell membrane and enter the cell with high efficiency. Cell membrane-permeability should increase the efficiency with which the oligonucleotides can hybridize with intracellular target DNA and RNA molecules.
  • the imaging agent should be radio-opaque in the region of the photon energy spectrum used in diagnostic radiographic imaging. The imaging agent should also be resistant to degradation by nucleases.
  • one embodiment of the functional imaging agent of the present invention is a cell membrane-permeable radio-opaque oligonucleotide capable of binding to intracellular target DNA or RNA molecules.
  • One embodiment of the imaging agent may use an oligonucleotide with a predetermined nucleotide sequence capable of hybridizing to a complementary nucleotide sequence present in abnormal or diseased body tissue.
  • the selected oligonucleotide may have a sequence complementary to an RNA or DNA target sequence expressed only in malignant tissue, only in normal tissue, or expressed at a different level in malignant tissue than in nonmalignant tissue.
  • the radio-opacity of the imaging agent and its accumulation in cells containing the targeted nucleic acid sequence thus permits the detection of a predetermined nucleic acid sequence in vivo in a radiographic imaging procedure using the imaging methods of the present invention.
  • a radio-opaque moiety is attached via a covalent linkage arm to the oligonucleotide at its 5'-terminus.
  • the radio-opaque moiety and linkage arm may be attached to the oligonucleotide at its 3'-terminus.
  • the linkage arm is made sufficiently long so that the radio-opaque moiety does not impede hybridization of the oligonucleotide with the target molecule.
  • a linkage arm of approximately 5-6 carbons, or approximately 5 - 6 ⁇ in length places the radio-opaque moiety a sufficient distance from a 5'-terminal nucleotide to prevent interference of hybridization of the oligonucleotide with a target sequence.
  • a long linkage arm may also increase lipophilicity of the imaging agent and enhance its entry into cells.
  • an aromatic ring bonded to iodine atoms may be used as the radio-opaque moiety to provide strong carbon-iodine bonds and consequent resistance to deiodination in vivo.
  • the imaging agent is capable of entering and exiting the cell via passive diffusion across the cell membrane.
  • the imaging agent molecule may be made lipophilic by either or both of two modifications of the native oligonucleotide.
  • First, negatively charged phosphodiester linkages in the oligonucleotide backbone may be partially or completely replaced by formacetal, aminohydroxy, or other nonionic internucleotide linkages.
  • Second, the oligonucleotide may be made additionally lipophilic. Methods for increasing lipophilicity include addition of hydrophobic moieties, such as an upper alkyl chain, to the 3'- or 5'-terminus of the oligomer. Lipophilic additions may also be made to one or more of the nucleotides with substitutions in purines, pyrimidines, or sugars.
  • radio-opaque imaging agent The general form of one embodiment of the radio-opaque imaging agent is wherein:
  • the internucleotide linkages of the S moiety may comprise nonionic linkages, including but not limited to formacetal or aminohydroxy linkages, between the C-5' position of the nucleotide sugar and the C-3' position of the adjacent nucleotide sugar.
  • one or more lipophilic groups including but not limited to C 6 - C 30 alkyl chains, may be attached at one or more locations on the S moiety, the X moiety, and the L moiety.
  • Functionalized groups including hydrophilic groups containing one or more hydroxyls or carbamoyls, may be also optionally be substituted at one or more positions of the X moiety to shield the radio-opacifying atom or atoms from causing chemotoxic responses in vivo.
  • a oligonucleotide dimer is substituted with an aminohydroxy internucleotide linkage for the native phosphodiester linkage and a C 8 alkyl chain is substituted at a 2'-sugar position of the oligomer.
  • the oligomer is linked to a radio-opaque moiety by means of a C 6 alkylamido linkage arm. One end of the linkage arm is bonded to the 5'-terminus of the oligomer, and the other end is bonded to a triiodophenyl moiety.
  • the triiodophenyl configuration of the radio-opaque moiety provides strong carbon-iodine bonds and resistance to deiodination in vivo.
  • the embodiments described in the present invention are directed toward the detection of nucleic acids expressed in malignant tissue, it will be evident to one skilled in the art that the method may be adapted for the radiographic detection of nucleic acids present in abnormal tissue in a wide variety of diseases.
  • the method may additionally be also used to detect the presence of any nucleic acid sequence present in tissue, whether the nucleic acid originates in the tissue itself or in foreign organisms such as bacteria or viruses present in the tissue.
  • the specific oligonucleotide sequence to be used will be determined by the complementary DNA or RNA sequence to be detected.
  • Fatty acids generally enter cells through passive diffusion [ Trigatti BL et al.: Biochem. J. 313: 487-394 (1996 ); Kamp F et al.: Biochemistry 34: 11928-11937 (1995 ); Kamp F et al.: Biochemistry 32: 11074-11086 (1993 )].
  • a portion of fatty acids undergo ⁇ -oxidation.
  • the first step in this metabolic pathway is activation of the fatty acid molecule by combination with coenzyme A (CoASH) in the presence of ATP to form acyl CoASH. This step is catalyzed by fatty acyl coenzyme A synthetase, and occurs in the endoplasmic reticulum and the outer mitochondrial membrane.
  • CoASH coenzyme A
  • fatty acids which enter myocardial cells is primarily incorporated into cellular triglycerides and membrane phospholipids. It has been demonstrated that the rates of ⁇ -oxidation and esterification of fatty acids are reduced in a wide range of myocardial disorders. Imaging of intracellular fatty acid metabolism using radiolabeled fatty acids in conjunction with SPECT and PET imaging devices has been shown to be an accurate diagnostic indicator of myocardial abnormality.
  • a non-radioactive, radio-opaque imaging agent comprised of a long-chain fatty acid attached to a radio-opaque moiety.
  • the imaging agent After administration to a patient, the imaging agent rapidly enters myocardial cells via passive diffusion across the cell membrane.
  • the tissue distribution of this imaging agent may be imaged using the single and multiple beam imaging methods described herein. .
  • Example 5 shows an imaging agent comprising an ⁇ -iodophenyl-substituted straight-chain fatty acid, 15-( p -Iodophenyl)pentadecanoic acid (IPPA).
  • IPPA 15-( p -Iodophenyl)pentadecanoic acid
  • the imaging agent is non-radioactive, which allows its use in cardiac imaging procedures using standard radiographic imaging devices. The need for synthesis of radiopharmaceuticals and gamma camera imaging is thereby eliminated.
  • the iodophenyl configuration provides a strong carbon-iodine bond and consequent resistance to deiodination in vivo.
  • Example 5 is lipophilic, and enters and exits the cell via passive diffusion across the cell membrane. The computed logP of Example 5 is 8.09.
  • variants of the non-radioactive, radio-opaque fatty acids described here may be readily synthesized.
  • these variants include the replacement of straight chain fatty acids with methyl-branched and p-phenylene-bridged fatty acids to increase tissue retention time [ Torikuza K et al.: Jpn. J. Nucl. Med. 28: 681-690 (1991 ); Eisenthut M et al.: Int. J. Rad. Appl. Instrum. 39: 639-649 (1988 )].
  • radio-opaque functional imaging agent shown above are designed for the detection of enzymes, nucleic acids, and fatty acids.
  • some of the embodiments of the present invention may be primarily used for the diagnosis of malignant tissue.
  • radiographic imaging agents with a wide variety of diagnostic functions may be developed using the design principles disclosed in the present invention.
  • cell membrane-permeable imaging agents may be synthesized which selectively bind to carbohydrates, lipids, other intracellular molecules, or cell structures or organelles. The system and method may thus be modified to provide radiographic detection of other cellular targets of diagnostic importance.
  • the radio-opaque element in the imaging agent is iodine.
  • other elements exhibiting sufficient radio-opacity in the photon energy spectrum used in radiography, and possessing acceptable physiological and toxicological characteristics, may be incorporated into the radio-opaque moiety of the imaging agent.
  • the choice of the element will depend on the goal of the diagnostic imaging procedure, the necessary physical and chemical characteristics of the imaging agent, and the energy spectrum of the transilluminating X-ray beam.
  • FIG.1 is a block diagram of a first embodiment of the imaging system, as used in an imaging procedure performed with a single, continuous spectrum, polyenergetic X-ray transilluminating beam.
  • a cell membrane-permeable radio-opaque imaging agent 11 is administered to a patient. During a predetermined time interval the imaging agent accumulates in the patient's normal body tissue 12, and at a different rate in any abnormal tissue 13 that may be present.
  • An X-ray illumination source 20 which may include an ordinary X-ray tube with a tungsten anode 21, produces a continuous spectrum polyenergetic beam 22.
  • a first collimator 23 directs the beam.
  • a second collimator 25 further directs the beam.
  • An X-ray image receptor 31, which may be radiographic film, a film/intensifying screen combination, a stimulable phosphor storage plate, a fluoroscopic image intensifier, an amorphous silicon sensor array, a CCD/scintillator combination, or another type of X-ray sensitive receptor, acquires a radiographic image of body tissue during transillumination by beam 22.
  • a receptor interface 38 acquires 37 the received image in a manner dependent on the type of receptor 31.
  • the film may be processed, and then viewed directly or scanned and digitized by the interface.
  • the receptor is a stimulable phosphor storage plate, the plate is read out and digitized by the interface.
  • the receptor is a fluoroscopic image intensifier or CCD/scintillator combination, the analog output of the detector is digitized by the interface.
  • the receptor is an amorphous silicon sensor array, the analog output is digitized by the interface or a digital output, if available, may be used directly.
  • Receptor interface 38 transfers the digitized image data to an image processing system 32, which may be a computer, over signal lines 39.
  • a block diagram of image processing system 32 is shown in FIG. 1A .
  • Components of the image processing system may all be contained on a single integrated circuit or distributed on multiple integrated circuits.
  • a processor 51 may be a microprocessor, such as a Pentium Pro, or a general purpose programmable computer, or a dedicated digital signal processor (DSP) which is programmed to perform methods of the invention.
  • the software of image processing system 32 may be stored in program memory 52, which may be ROM or RAM, or on a CD-ROM, or on a hard disk drive or on other storage media, or may be stored on processor chip 51.
  • I/O control 55 receives digitized image data from image receptor 38 ( FIGS. 1 and 2 ) over signal lines 39. The digitized image data is stored in image memory 54. After image processing, display controller 53 outputs the display image over signal lines 35 to a display monitor 33 ( FIGS. 1 and 2 ).
  • Image processing system 32 may correct the data for linearity, converts the data to an image display format, and outputs the display image to a display monitor 33 over signal lines 35, and optionally to a hard copy device (not shown) which may be a printer. Image processing system 32 may also store the image in digital form on a hard disk, a tape drive, or another storage device (not shown).
  • the image will display the radiographic density contributed by the imaging agent combined with the radiographic density contributed by soft tissue and bone also present in the beam path. If a sufficiently large quantity of imaging agent accumulates, it may be detected and localized by direct inspection of the radiographic image. Optionally, the image may be digitized and processed using the standard methods of digital radiography, including digital filtering and contrast enhancement. If the radiographic density of the accumulated imaging agent is too low to be detected when combined with the radiographic density of soft tissue and bone, the multiple beam imaging system and method described in sections D and E may be used to isolate the radiographic density contributed by the imaging agent.
  • FIG. 2 is a block diagram of a second embodiment of the imaging system, as used in a multiple beam imaging procedure performed with two or more quasi-monoenergetic X-ray transilluminating beams with different mean energy spectra.
  • three transilluminating beams are used.
  • Cell membrane-permeable radio-opaque imaging agent 11 is administered to a patient. During a predetermined time interval the imaging agent accumulates in the patient's normal body tissue 12, and in any abnormal tissue 13 that may be present.
  • X-ray illumination source 20 which may include an ordinary X-ray tube with a tungsten anode 21, produces continuous spectrum polyenergetic beam 22.
  • First collimator 23 directs the beam.
  • An X-ray filter apparatus 40 comprises a filter wheel 45, X-ray filters 41a, 42a, 43a (shown on FIG. 3B ), a shaft 44, a positioner 46, and position control signals 47 generated by image processing system 32.
  • FIGS. 3A and 3B depict X-ray filter apparatus 40 and its relation to X-ray illumination source 20 in greater detail.
  • Positioner 46 which may be a stepping motor whose angular shaft position is controlled by control signals 47, is mechanically coupled to filter wheel 45 through shaft 44. Control signals 47 may be generated by image processing system 32.
  • Positioner 46 rotates the filter wheel to sequentially interpose each of filters 41a, 42b, 43c in the path of beam 22. As each of the filters is interposed in beam 22, the positioner stops rotation of the filter wheel, and a separate radiographic image is acquired. The filter wheel is then rotated to interpose the next filter in the path of beam 22.
  • Filter wheel 45 preferably comprises a circular mounting disc 48, made from a highly radio-opaque material, containing a plurality of cut-out apertures 41b, 42b, 43b arranged in a regularly spaced circular array.
  • X-ray filters 41a, 42a, 43a are concentrically mounted on apertures 41b, 42b, 43b, respectively.
  • Each X-ray filter contains a different substance that converts polyenergetic X-ray beam 22 into a quasi-monoenergetic transilluminating beam 24 with a unique mean energy spectrum.
  • the mean energy spectrum of each filtered beam is determined by the X-ray absorption characteristics of the substance contained in the filter.
  • the method for selection of the spectra of the beam is described in section E, and the method for selection of the filters is described in section G.
  • FIG. 2 shows second collimator 25, which further directs quasi-monoenergetic transilluminating beam 24 after it has passed through the X-ray filter.
  • X-ray image receptor 31 which may be radiographic film, a film/intensifying screen combination, a stimulable phosphor storage plate, a fluoroscopic image intensifier, an amorphous silicon sensor array, a CCD/scintillator combination, or another type of X-ray sensitive receptor, acquires a radiographic image of body tissue during transillumination by beam 22.
  • a receptor interface 38 acquires 37 the received image in a manner dependent on the type of receptor 31. If the receptor is film or a film/intensifying screen combination, the film may be processed, scanned and digitized by the interface.
  • the receptor is a stimulable phosphor storage plate
  • the plate is read out and digitized by the interface.
  • the receptor is a fluoroscopic image intensifier or CCD/scintillator combination
  • the analog output of the detector is digitized by the interface.
  • the receptor is an amorphous silicon sensor array
  • the analog output is digitized by the interface, or a digital output, if available, may be used directly.
  • Receptor interface 38 transfers the digitized image data to image processing system 32 over signal lines 39.
  • a block diagram of image processing system 32 is shown in FIG. 1A .
  • Components of the image processing system may all be contained on a single integrated circuit or distributed on multiple integrated circuits.
  • a processor 51 may be a microprocessor, such as a Pentium Pro, or a general purpose programmable computer, or a dedicated digital signal processor (DSP) which is programmed to perform methods of the invention.
  • the software of image processing system 32 may be stored in program memory 52, which may be ROM or RAM, or on a CD-ROM, or on a hard disk drive or other storage media, or may be stored on processor chip 51.
  • I/O control 55 receives digitized image data from image receptor 38 ( FIGS. 1 and 2 ) over signal lines 39. The digitized image data is stored in image memory 54.
  • display controller 53 After image processing, display controller 53 outputs the display image over signal lines 35 to a display monitor 33 ( FIGS. 1 and 2 ). I/O control 55 may also receive input signals from image controller 34 via a keyboard or mouse over signal lines 36. The image control and display methods are described in detail in section F. By means of these input signals, the viewer may switch between the display of either an anatomical or functional images, or, alternatively, display variable proportions of anatomical and functional images on a single image in registration.
  • Image processing system 32 linearizes the digitized data and performs an image processing procedure to enhance and display the image. (The image acquisition and processing procedures are described in section E). Image processing system 32 outputs the display image to a display monitor 33 over signal lines 35, and optionally to a hard copy device (not shown) which may be a printer. Image processing system 32 may also store the image in digital form on a hard disk, a tape drive, or another storage device (not shown).
  • An image controller 34 which may be a keyboard or a mouse, is connected to image processing system 32 over signal lines 36.
  • the viewer uses image controller 34 to vary one or more of the display coefficients applied by the image processing procedure to the anatomical and functional images to be displayed. Changing the value of the display coefficients varies the degree to which imaging agent, and soft tissue and bone contribute radiographic density to the display image. The viewer may thus superimpose a variable level of the anatomical image (soft tissue and bone) on the functional image (accumulated imaging agent).
  • FIG. 4 is a block diagram of a third embodiment of the imaging system, as used in a imaging procedure performed with a single, continuous spectrum, polyenergetic X-ray transilluminating beam. After the beam transilluminates the patient's body tissue, it is sequentially filtered to generate multiple beams with different mean energy spectra, and a separate radiographic image is acquired during generation of each beam.
  • Cell membrane-permeable radio-opaque imaging agent 11 is administered to a patient. During a predetermined time interval the imaging agent accumulates in the patient's normal body tissue 12, and in any abnormal tissue 13 that may be present.
  • X-ray illumination source 20 which may include an ordinary X-ray tube with a tungsten anode 21, produces continuous spectrum polyenergetic beam 22.
  • First collimator 23 directs the beam.
  • a second collimator 25 further directs beam 22, which transilluminates the patient's body tissue 12, 13.
  • each X-ray filter 49a, b, c is interposed in temporal sequence between the patient's body tissue and image receptor 31.
  • Each of the filters sequentially converts polyenergetic beam 22 into a quasi-monoenergetic beam with a different mean energy spectrum.
  • each X-ray filter may comprise a thin sheet of a substance with selected X-ray attenuation characteristics. This substance, which may have a K-absorption edge at a predetermined photon energy, filters the beam to enable the transmission of a predetermined energy spectrum to the image receptor.
  • the method for selection of the spectra of the beams is described in section E, and the method for selection of the filters is described in section G.
  • the filter sheet may be positioned adjacent to image receptor 31, which may comprise a film/intensifying screen combination, a stimulable phosphor storage plate, a fluoroscopic image intensifier, an amorphous silicon sensor array, a CCD/scintillator combination, or another type of X-ray sensitive receptor.
  • image receptor 31 may comprise a film/intensifying screen combination, a stimulable phosphor storage plate, a fluoroscopic image intensifier, an amorphous silicon sensor array, a CCD/scintillator combination, or another type of X-ray sensitive receptor.
  • Each X-ray filter contains a different substance that converts polyenergetic X-ray beam 22 into a quasi-monoenergetic beam 24 with a unique mean energy spectrum.
  • the mean energy spectrum of each filtered beam is determined by the X-ray absorption characteristics of the substance contained in the filter.
  • the method for selection of the spectra of the beam is described in section E, and the method for selection of the filters is described in section G.
  • X-ray image receptor 31 which may be radiographic film, a film/intensifying screen combination, a stimulable phosphor storage plate, a fluoroscopic image intensifier, an amorphous silicon sensor array, a CCD/scintillator combination, or another type of X-ray sensitive receptor, acquires a radiographic image of body tissue during transillumination by beam 22.
  • a receptor interface 38 acquires 37 the received image in a manner dependent on the type of receptor 31. Subsequent acquisition and processing of the radiographic images are similar to those described earlier in this section for the multiple beam imaging system using the filter wheel apparatus.
  • the requirement for a sequence of transilluminating X-ray beams with different mean energy spectra is satisfied by filtration of a polyenergetic beam, in temporal sequence, through substances with selected X-ray absorption characteristics.
  • this requirement may also be satisfied by other means.
  • an X-ray monochromator may be sequentially tuned to produce monoenergetic beams with the required energy spectra.
  • a tuned synchrotron may be used to produce monoenergetic beams with the required spectra.
  • the multiple beam imaging method generates a radiographic image which emphasizes the radiographic density of accumulated imaging agent and almost completely cancels the radiographic density of the soft tissue and bone present in the beam path.
  • body tissue being examined is sequentially transilluminated by two or more beams with different preselected mean energy spectra, and a separate image is acquired during transillumination by each beam.
  • the separate acquired images are then combined, using image weighting coefficients, into a single image.
  • the transilluminating beams may be quasi-monoenergetic or monoenergetic, and their spectra are selected based on the K-absorption edge of the radio-opaque element contained in the imaging agent.
  • K-absorption edge For each element in the periodic table there is a unique profile of X-ray attenuation over the photon energy spectrum, and, most importantly, a characteristic energy at which X-ray attenuation sharply increases. This abrupt increase in attenuation is known as the K-absorption edge.
  • the K-absorption edge for each element is unique, and is monotonically related to the atomic number of the element.
  • one beam is selected to have a mean energy spectrum just below the K-absorption edge of the radio-opaque element in the imaging agent, and a second beam is selected to have a mean energy spectrum just above the K-absorption edge of the radio-opaque element.
  • the principle of operation of the method is illustrated in the following example. Assume that a quantity of radio-opaque imaging agent has accumulated in an area of body tissue under examination. The tissue is first transilluminated by beam E 1 with a mean energy spectrum just below the K-absorption edge of the radio-opaque element in the imaging agent, and image X 1 is acquired. Absorption of beam E 1 by the imaging agent will be relatively low, and the radiographic density it contributes to image X 1 will be correspondingly high.
  • the tissue is then transilluminated by beam E 2 with a mean energy spectrum just above the K-absorption edge of the radio-opaque element in the imaging agent, and image X 2 is acquired. Because there is a sharp increase in X-ray attenuation at the K-absorption edge of the element, absorption of beam E 2 by the imaging agent will be relatively high, and the radiographic density it contributes to image X 2 will be correspondingly low.
  • Soft tissue will contribute a nearly equal level of radiographic density to image X 1 and to image X 2 . This is because the K-absorption edges of the elements which comprise soft tissue (predominantly carbon, hydrogen, oxygen, and nitrogen), are located well below the mean energy spectra of beams E 1 and E 2 . Thus, the absorption of beams E 1 and E 2 by soft tissue will be nearly equivalent.
  • Bone will also contribute a nearly equal level of radiographic density to image X 1 and to image X 2 . This is because the K-absorption edges of the elements which comprise bone (predominantly carbon, hydrogen, oxygen, nitrogen, and calcium) are likewise located well below the mean energy spectra of beams E 1 and E 2 . Thus, the absorption of beams E 1 and E 2 by bone will be nearly equivalent.
  • a viewer may switch between a display showing image Z , and an anatomical image (e.g. image X 1 ) which is aligned in registration with image Z .
  • an anatomical image e.g. image X 1
  • image Z may be combined with image X 1 or image X 2 , in registration, to produce a single anatomical and functional image.
  • a third beam E 3 may be generated with a mean energy spectrum well above the mean energy spectrum of beam E 2 , and a third image X 3 acquired during transillumination of the tissue by beam E 3 .
  • Appropriate weighting of image X 3 , and its combination with weighted images X 1 and X 2 produces a display image Z with almost complete cancellation of the radiographic density of soft tissue and bone.
  • a flow chart of the image acquisition and processing procedure 80 is shown in FIG. 8 .
  • a radio-opaque functional imaging agent is administered 81 to a patient.
  • the imaging agent accumulates in the patient's body tissue.
  • the patient is then positioned 83 appropriately between the X-ray source and image receptor.
  • An X-ray beam E 1 transilluminates 84 the body tissue being examined, and a radiographic image R 1 is acquired 85.
  • the sequence of transillumination and image acquisition is repeated 86 for beam E 2 and image R 2 , and beam E 3 and image R 3 , respectively.
  • Radiographic image R 1 is digitized 87 to generate digital image D 1 .
  • the radiographic image may be digitized immediately after acquisition of each image, digitized after acquisition of the entire series of images, or stored for digitization at some later time. After digitization, image processing may be performed immediately, or the digital arrays may be stored in random-access memory, on a hard drive, on tape, or on other digital storage media for later processing.
  • D 1 digitized R 1
  • corrections to linearize the transfer function of the X-ray image receptor may then be applied 88 to the digital array.
  • the correction may be implemented by one or more hardware-based lookup tables.
  • the input to the lookup tables may be the uncorrected output value of the analog-to-digital converter and the output of the lookup table would then be the linearized.
  • the correction may be performed in software by one or more lookup tables stored in random-access memory , on a hard disk, or on other storage media.
  • D 1 ⁇ corrected D 1
  • a number of image receptor systems are now available and others are being developed for acquiring radiographic images in a form suitable for digital processing. These receptor systems include, but are not limited to, stimulable phosphor storage plates, fluoroscopic image intensifiers, amorphous silicon sensor arrays, and CCD/scintillator combinations.
  • the image receptor used in the present invention is characterized by a) a substantially linear relationship between X-ray photon energy input and detector signal output, and b) a substantially linear detector response in the photon energy spectrum between approximately 10 keV and approximately 60 keV. If an image receptor with nonlinear gain or spectral response characteristics is used in the present invention, the nonlinearity may be appropriately corrected by hardware or software.
  • the correction is based on the predetermined response of the image receptor to the range of photon input levels and energy spectra used in the imaging procedure.
  • the image array is therefore assumed to have a linear relationship to the input X-ray signal after correction 88.
  • the modifications necessary to achieve this correction are mathematically straightforward, and will be evident to one of ordinary skill in the art.
  • Image processing system 32 multiplies 90 each pixel value in image X 1 by weighting coefficient w 1 .
  • an additional higher order term may be added to compensate for the slight beam hardening, or increase in mean beam energy, and resulting small decrease in effective mass attenuation coefficient that occurs when each quasi-monoenergetic beam passes through a thickness of tissue or bone. This term is equal to X 1 2 multiplied by hardening coefficient h 1 .
  • Image digitization, correction, log conversion, and image weighting is repeated 91 for radiographic images R 2 and R 3 .
  • the image combination formula, which in one embodiment is Z Y 1 + Y 2 + Y 3 is then performed 92 to yield display image Z.
  • Image Z is displayed 93 on the display monitor, as shown in FIG. 9 .
  • image Z may be modified by the user to display varying proportions of imaging agent, soft tissue and bone present in the beam path.
  • Image Z may also be converted to hard copy, and may be stored in random-access memory, on a hard drive, on tape, or on another digital storage medium for archiving and for later viewing.
  • Table 2 shows the mean energy spectra for beams E 1 , E 2 , and E 3 , the corresponding image weighting coefficients w 1 , w 2 , and w 3 , and hardening coefficients h 1 , h 2 , and h 3 used in one embodiment of the multiple beam imaging method. These coefficients are used in the image weighting step 90 of FIG. 8 .
  • TABLE 2 Beam keV Image w h E 1 31.05 X 1 -30.5 0.11 E 2 37.10 X 2 99.7 -0.43 E 3 44.10 X 3 -67.4 0.25
  • Table 3 shows typical concentrations of imaging agent, soft tissue and bone present in the transilluminating X-ray beam path and their attenuation of beams E 1 , E 2 , and E 3 .
  • the table also shows levels of radiographic density present on acquired images X 1 , X 2 and X 3 , and the radiographic density present on display image Z after application of the image processing procedure described above.
  • TABLE 3 Image component Thickness gm/cm 2 Beam Transmittance Relative density E 1 E 2 E 3 Iodine 0.001 99.03 97.68 98.35 1.000 Soft tissue 12.000 69.42 74.93 78.91 0.009 Bone 3.000 24.85 40.11 58.27 0.039
  • a flow chart of the image control procedure 100 is shown in FIG. 9 .
  • the weighted and combined image Z resulting from step 92 ( FIG. 8 ) is an image of relatively low visual contrast.
  • a contrast enhancement procedure such as a level shift and histogram stretch, may be first performed 101 to enhance the visual contrast of image Z, to produce image Z'.
  • each of unweighted, uncombined images X 1 , X 2 and X 3 is an anatomical image, represented by radiographic density contributed by soft tissue and bone, and also containing radiographic density contributed by accumulation of the radio-opaque imaging agent.
  • Weighted and combined image Z is solely a functional image. The viewer may interactively vary the displayed proportions of the anatomical and functional images, and the combined images will be displayed on a single image in complete registration.
  • Display coefficient f represents the displayed proportion of the functional image
  • display coefficient ⁇ which is forced to (1 - f ), represents the displayed proportion of the anatomical image.
  • the value of f is initially set at 1.0 when a new image Z' is displayed, so that only the functional image is first displayed. While image Z' is displayed 102 on the display monitor, image processing system 32 ( FIG. 2 ) periodically tests 103 for a change in coefficient f , which the viewer selects using image controller 34 ( FIG. 2 ). When a change is detected in coefficient f, the image processing system combines 104 the selected proportions of functional image Z and image X 1 , performs contrast enhancement, and redisplays 102 the resulting new image Z' on the display monitor. Image Z ' may also be stored in random- access memory, on a hard drive, or on another storage device.
  • the viewer While viewing the displayed image, the viewer may thereby interactively superimpose a variable proportion of the anatomical image on the functional image. Since the anatomical and functional images are displayed in complete registration, this capability facilitates precise localization of malignant tissue, or other tissue which is labeled by the imaging agent, with reference to nearby anatomical landmarks.
  • a small unwanted residual density contributed by soft tissue or bone may remain on display image Z after image processing using the predetermined weighting coefficients used in the image processing procedure described in section E.
  • the viewer may interactively adjust the image weighting coefficient of image X 3 to completely cancel this residual.
  • image processing system 32 While image Z ' is displayed 102 on the display monitor, image processing system 32 ( FIG. 2 ) periodically tests 105 for a change in weighting coefficient w 3 , which is controlled by the viewer using image controller 34 ( FIG. 2 ).
  • a change in the value of weighting coefficient w 3 changes the contribution of image Y 3 to display image Z, and therefore the degree to which soft tissue and bone are canceled in image Z.
  • the image processing system recomputes the image 106, 107 using the new coefficient w 3 , performs contrast enhancement 101 to stretch the recomputed image to full scale, and displays 102 the recomputed image Z' on the display monitor.
  • an X-ray filter apparatus sequentially generates multiple quasi-monoenergetic beams with different mean energy spectra.
  • alternative methods for generating multiple quasi-monoenergetic or monoenergetic X-ray beams, each having a unique energy spectrum may be also be used with the present invention.
  • Operation of the filter apparatus is based on the principle that a polyenergetic X-ray beam may be converted into a quasi-monoenergetic beam, with a unique mean energy spectrum, by filtering the polyenergetic beam through a substance containing an element with selected X-ray attenuation characteristics. Specifically, a substance with a K-absorption edges at a selected photon energy is used to generate a beam with the desired energy spectrum.
  • K-absorption edge An example of a K-absorption edge is shown in FIG. 5A .
  • K-absorption edge 61b appears as an abrupt increase in the mass attenuation coefficient at 33.1 keV.
  • Each X-ray filter 41a, 42a, and 43a ( FIG. 3B ) contains a different substance which transforms polyenergetic X-ray beam 22 into a quasi-monoenergetic transilluminating beam 24 with a unique mean energy spectrum.
  • the mean energy spectrum of transilluminating beam E 1 should be just below the K-absorption edge of the radio-opaque element whose radiographic density is to be isolated.
  • the mean energy spectra of beam E 2 should be above the K-absorption edge of the radio-opaque element.
  • a third transilluminating beam E 3 is used and should have a mean energy spectrum above that of beam E 2 .
  • the radio-opaque element used is iodine.
  • substances which may be used to filter polyenergetic beams to convert them into quasi-monoenergetic beams with appropriate mean energy spectra include iodine, cerium, and brass.
  • the X-ray filters may be implemented with cylindrical cells containing solutions of the substances selected for beam filtration, or with solid disks of metal.
  • the required concentrations of the filter substances in solution and the thicknesses of the solid metal filters are readily calculated using their mass attenuation coefficients.
  • I( E ) is the output intensity of the beam
  • I 0 ( E ) is the incident intensity of the beam
  • ⁇ is the attenuation coefficient of the substance at energy E
  • ⁇ is the density of the substance
  • x is the mass thickness (mass per unit area) of the substance.
  • FIGS. 5A through 7B show the X-ray mass attenuation coefficients of iodine, cerium, and brass plotted vs. photon energy, and the conversion of polyenergetic X-ray beams to quasi-monoenergetic beams with different mean energy spectra by filters containing selected thicknesses of these substances.
  • the K-absorption edge 61b of iodine is at 33.1 keV.
  • FIG. 5B shows normalized energy spectra of unfiltered and iodine-filtered X-ray beams.
  • Graph 61c (dashed line) shows the spectrum of an unfiltered beam generated by a tungsten anode source operated at 50 kVp.
  • X-ray filter 41a ( FIG. 3B ) contains a solution of an iodine compound in which the mass thickness of iodine is 0.200 gm/cm 2 .
  • a polyenergetic 50 kVp beam with spectrum 61c is converted by this filter to a quasi-monoenergetic beam with spectrum 61d, as shown in FIG. 5B .
  • Spectrum 61c of the unfiltered beam is polyenergetic and relatively broad.
  • the spectrum of iodine-filtered beam 61d is narrower and quasi-monoenergetic.
  • Iodine-filtered beam 61d has an energy peak at 33 keV and a mean energy spectrum of 31.1 keV.
  • the K-absorption edge 62b of cerium is at 40.0 keV.
  • FIG. 6B shows normalized energy spectra of unfiltered and cerium-filtered beams.
  • X-ray filter 42a contains a solution of a cerium compound in which the mass thickness of cerium is 0.380 gm/cm 2 .
  • a polyenergetic 50 kVp beam with spectrum 62c is converted by this filter to a quasi-monoenergetic beam with spectrum 62d, as shown in FIG. 6B .
  • Cerium-filtered beam 62d has an energy peak at 40 keV and a mean energy spectrum of 36.6 keV.
  • FIG. 7A shows a graph 63a of the mass attenuation coefficient of brass as a function of photon energy.
  • FIG. 7B shows normalized energy spectra of unfiltered and brass-filtered beams.
  • X-ray filter 43a is a thin circular brass disc in which the mass thickness of brass is 1.500 gm/cm 2 .
  • a polyenergetic 50 kVp beam with spectrum 63c is converted by this filter to a quasi-monoenergetic beam with spectrum 63d, as shown in FIG. 7B .
  • Brass-filtered beam 63d has an energy peak at 46 keV and a mean energy spectrum of 45.3 keV.
  • Table 4 summarizes the filtration parameters for generation of each of the quasi-monoenergetic transilluminating beams from a 50 kVp polyenergetic input beam and the energy characteristics of the filtered beams used to generate display image Z as described in section E.
  • TABLE 4 Beam Filter substance Thickness gm/cm 2 Beam mean E E 1 Iodine 0.200 31.05 E 2 Cerium 0.380 37.00 E 3 Brass 1.340 45.01

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medical Informatics (AREA)
  • Engineering & Computer Science (AREA)
  • Radiology & Medical Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Radiography Using Non-Light Waves (AREA)

Claims (31)

  1. Système d'imagerie radiographique d'un tissu corporel (12) comprenant :
    a) un agent d'imagerie ;
    b) un moyen d'administration dudit agent d'imagerie à un patient ;
    c) un moyen (20) de production d'un faisceau de rayons X ;
    d) un moyen (31) d'acquisition d'images radiographiques, situé à côté dudit patient opposé audit moyen de production d'un faisceau de rayons X ;
    caractérisé en ce que
    ledit agent d'imagerie est un agent d'imagerie radioopaque perméable à une membrane cellulaire qui est susceptible d'entrer dans une cellule par diffusion passive et qui se lit à une cible cellulaire.
  2. Système selon la revendication 1, caractérisé en ce que ledit moyen (20) de production d'un faisceau de rayons X est susceptible de produire une pluralité de faisceaux ayant différents spectres d'énergie prédéterminés et qui comprend en outre un moyen (32) de réalisation d'une combinaison pondérée d'une pluralité desdites images radiographiques afin de produire une seule image.
  3. Système selon la revendication 2, caractérisé en ce que ladite pluralité de faisceaux est quasimonoénergétique.
  4. Système selon la revendication 2, caractérisé en ce que ladite pluralité de faisceaux est monoénergétique.
  5. Système selon les revendications 2 à 4, caractérisé en ce que 2 faisceaux sont produits.
  6. Système selon les revendications 2 à 4, caractérisé en ce que plus de 2 faisceaux sont produits.
  7. Système selon les revendications 2 à 6, caractérisé en ce que ledit moyen (41a, 42a, 43a) de production d'une pluralité de faisceaux ayant différents spectres d'énergie prédéterminés est placé entre ledit moyen (20) de production d'un faisceau de rayons X et ledit patient (12).
  8. Système selon les revendications 2 à 6, caractérisé en ce que ledit moyen (49a, 49b, 49c) de production d'une pluralité de faisceaux ayant différents spectres d'énergie prédéterminés est placé entre ledit patient (12) et ledit moyen (31) d'acquisition d'images radiographiques.
  9. Système selon les revendications 2 à 8, caractérisé en ce qu'il comprend en outre un moyen (35) d'affichage des proportions variables de densité radiographique apportées par ledit agent d'imagerie, le tissu mou et l'os à ladite image unique.
  10. Système selon les revendications 1 à 9, caractérisé en ce que ladite cible cellulaire est une structure cellulaire.
  11. Système selon les revendications 1 à 9, caractérisé en ce que ladite cible cellulaire est un organite cellulaire ou une molécule.
  12. Système selon les revendications 1 à 9, caractérisé en ce que ladite cible cellulaire est choisie dans le groupe constitué par les protéines, les acides nucléiques, les coenzymes et les lipides.
  13. Système selon les revendications 1 à 9, caractérisé en ce que ladite cible cellulaire est une enzyme.
  14. Système selon les revendications 1 à 9, caractérisé en ce que ladite cible cellulaire est l'hexokinase.
  15. Système selon les revendications 1 à 14, caractérisé en ce que ledit agent d'imagerie est non radioactif.
  16. Système selon les revendications 1 à 15, caractérisé en ce que ledit agent d'imagerie s'accumule dans un tissu malin à taux différent de celui accumulé dans un tissu non malin.
  17. Système selon les revendications 1 à 15, caractérisé en ce que ledit agent d'imagerie s'accumule dans un tissu myocardique anormal à taux différent de celui accumulé dans un tissu myocardique normal.
  18. Système selon les revendications 1 à 17, caractérisé en ce que ledit agent d'imagerie possède un logP supérieur à 0,0.
  19. Composition ayant la formule générale X-L-S, dans laquelle :
    le fragment S est choisi parmi une pyranose, une furanose ou un oligonucléotide dans lequel la séquence nucléotidique comprend au moins deux résidus ;
    le fragment X est un groupe alkyle en C1-C8, alcoxy, alkylthio, alcényle, alkylaryle, alkylamino, alkylamido, amido ou arylamido substitué ou non substitué, dans lequel au moins un atome est substitué par un atome radio-opacifiant d'un élément ayant un nombre atomique de Z = 35 à Z = 74 ; et
    le fragment L est un groupe alkyle en C1-C8, alcoxy, alkylthio, alcényle, alkylaryle, alkylamino, alkylamido, amido ou arylamido substitué ou non substitué, lié au fragment S et au fragment X ;
    à condition que ledit agent d'imagerie radioopaque possède une valeur de logP supérieure à 0,0.
  20. Composition selon la revendication 19, caractérisée en ce que le fragment S est choisi parmi une pyranose ou une furanose, et la pyranose ou la furanose est substituée par un groupe hydroxy.
  21. Composition selon la revendication 20, caractérisée en ce que le fragment S est choisi parmi une pyranose ou une furanose, et la pyranose ou la furanose est substituée par un groupe 2-hydroxy.
  22. Composition caractérisée en ce que :
    le fragment S est choisi parmi une pyranose qui est une pyranose substituée de formule C6H11O5,
    le fragment X est un groupe aryle substitué de formule C6H2I3, et
    le fragment L est un groupe amidoaryle substitué de formule C6H3NH2NHCO.
  23. Composition caractérisée en ce que :
    le fragment S est choisi parmi une pyranose qui est une pyranose substituée de formule C6H11O5,
    le fragment X est un groupe aryle substitué de formule C6HI3CH2CH3, et
    le fragment L est un groupe amidoaryle substitué de formule C6H3NH2NHCO.
  24. Composition caractérisée en ce que :
    le fragment S est choisi parmi une pyranose qui est une pyranose substituée de formule C6H11O5,
    le fragment X est un groupe aryle substitué de formule C6I3(CONHCH3)2, et
    le fragment L est un groupe amidoaryle substitué de formule C6H3NH2NHCO.
  25. Composition selon la revendication 19, dans laquelle le fragment S est choisi parmi un oligonucléotide dans lequel la séquence nucléotidique comprend au moins deux résidus,
    caractérisée en ce que la liaison internucléotidique est non ionique.
  26. Composition selon la revendication 19, dans laquelle le fragment S est choisi parmi un oligonucléotide dans lequel la séquence nucléotidique comprend au moins deux résidus,
    caractérisée en ce qu'un ou plusieurs groupes lipophiles sont liés à au moins l'un des fragments constitués par le fragment S, le fragment X et le fragment L.
  27. Composition selon l'une quelconque des revendications 19 à 26, caractérisée en ce qu'elle est bidirectionnellement perméable à une membrane cellulaire.
  28. Composition selon l'une quelconque des revendications 19 à 27, caractérisée en ce qu'elle se lie en outre sélectivement à une cible cellulaire.
  29. Composition selon l'une quelconque des revendications 19 à 28, pour une utilisation en tant qu'agent de diagnostic.
  30. Composition selon l'une quelconque des revendications 19 à 28, pour une utilisation en tant qu'agent d'imagerie radioopaque.
  31. Composition selon l'une quelconque des revendications 19 à 28, pour une utilisation en tant qu'agent de diagnostic pour le diagnostic d'un tissu malin par imagerie radiographique.
EP99945495A 1998-09-08 1999-08-31 Systeme pour l'imagerie radiographique des tissus Expired - Lifetime EP1126788B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US149734 1998-09-08
US09/149,734 US6226352B1 (en) 1998-09-08 1998-09-08 System and method for radiographic imaging of tissue
PCT/US1999/020298 WO2000013590A2 (fr) 1998-09-08 1999-08-31 Systeme et procede pour l'imagerie radiographique des tissus

Publications (2)

Publication Number Publication Date
EP1126788A2 EP1126788A2 (fr) 2001-08-29
EP1126788B1 true EP1126788B1 (fr) 2011-08-24

Family

ID=22531568

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99945495A Expired - Lifetime EP1126788B1 (fr) 1998-09-08 1999-08-31 Systeme pour l'imagerie radiographique des tissus

Country Status (7)

Country Link
US (3) US6226352B1 (fr)
EP (1) EP1126788B1 (fr)
JP (1) JP2002524126A (fr)
AT (1) ATE521284T1 (fr)
AU (1) AU5808599A (fr)
ES (1) ES2372268T3 (fr)
WO (1) WO2000013590A2 (fr)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6751290B2 (en) 1998-09-08 2004-06-15 Veritas Pharmaceuticals, Inc. Radiographic assessment of tissue after exposure to a compound
US6226352B1 (en) * 1998-09-08 2001-05-01 Veritas Pharmaceuticals, Inc. System and method for radiographic imaging of tissue
US6723746B2 (en) 1998-09-08 2004-04-20 Veritas Pharmaceuticals, Inc. Functional radiographic imaging methods and agents
US20010038682A1 (en) * 1998-09-08 2001-11-08 Jesse Salb Radiographic assessment of tissue response to compounds
US7228165B1 (en) * 2000-06-26 2007-06-05 Boston Scientific Scimed, Inc. Apparatus and method for performing a tissue resection procedure
DE10056457C2 (de) * 2000-11-14 2002-11-07 Siemens Ag Verfahren zum Betrieb eines Magnetresonanzgeräts mit funktioneller Bildgebung
DE10064768B4 (de) * 2000-12-22 2006-12-07 Siemens Ag Verfahren zur Untersuchung eines Lebewesens mittels eines bildgebenden Verfahrens
US6614878B2 (en) * 2001-01-23 2003-09-02 Fartech, Inc. X-ray filter system for medical imaging contrast enhancement
US20020169639A1 (en) * 2001-05-09 2002-11-14 Jeffrey Yu Systems for generating radiology reports
US7006862B2 (en) * 2001-07-17 2006-02-28 Accuimage Diagnostics Corp. Graphical user interfaces and methods for retrospectively gating a set of images
US7130457B2 (en) * 2001-07-17 2006-10-31 Accuimage Diagnostics Corp. Systems and graphical user interface for analyzing body images
US20030028401A1 (en) * 2001-07-17 2003-02-06 Leon Kaufman Customizable lung report generator
US7209779B2 (en) * 2001-07-17 2007-04-24 Accuimage Diagnostics Corp. Methods and software for retrospectively gating a set of images
US6901277B2 (en) * 2001-07-17 2005-05-31 Accuimage Diagnostics Corp. Methods for generating a lung report
US7142703B2 (en) * 2001-07-17 2006-11-28 Cedara Software (Usa) Limited Methods and software for self-gating a set of images
US20030053951A1 (en) * 2001-07-26 2003-03-20 Millennium Pharmaceuticals, Inc. Use of non-invasive imaging technologies to monitor in vivo gene-expression
EP1292036B1 (fr) * 2001-08-23 2012-08-01 Nippon Telegraph And Telephone Corporation Méthodes et appareils de decodage de signaux numériques
US7127096B2 (en) * 2001-11-20 2006-10-24 Accuimage Diagnostics Corp. Method and software for improving coronary calcium scoring consistency
WO2003059149A2 (fr) * 2001-12-21 2003-07-24 Threshold Pharmaceuticals, Inc. Procede d'imagerie du cancer
US7636413B2 (en) * 2002-04-16 2009-12-22 General Electric Company Method and apparatus of multi-energy imaging
US6770893B2 (en) * 2002-05-13 2004-08-03 Visiongate, Inc. Method and apparatus for emission computed tomography using temporal signatures
AU2003252103A1 (en) * 2002-07-23 2004-02-09 Ge Medical Systems Global Technology Company, Llc Methods and systems for detecting components of plaque
US7149331B1 (en) 2002-09-03 2006-12-12 Cedara Software Corp. Methods and software for improving thresholding of coronary calcium scoring
US20040101088A1 (en) * 2002-11-27 2004-05-27 Sabol John Michael Methods and apparatus for discriminating multiple contrast agents
GB2401766B (en) * 2003-03-11 2006-03-15 Symetrica Ltd Improved gamma-ray camera system
US20040225531A1 (en) * 2003-05-07 2004-11-11 Serrano Laura Kathleen Computerized system and method for automated correlation of mammography report with pathology specimen result
US6968030B2 (en) * 2003-05-20 2005-11-22 General Electric Company Method and apparatus for presenting multiple pre-subject filtering profiles during CT data acquisition
US7046756B2 (en) * 2003-05-20 2006-05-16 General Electric Company Rotatable filter for a pre-subject CT collimator having multiple filtering profiles
US7120222B2 (en) * 2003-06-05 2006-10-10 General Electric Company CT imaging system with multiple peak x-ray source
US6950493B2 (en) * 2003-06-25 2005-09-27 Besson Guy M Dynamic multi-spectral CT imaging
US7343030B2 (en) * 2003-08-05 2008-03-11 Imquant, Inc. Dynamic tumor treatment system
US8055323B2 (en) * 2003-08-05 2011-11-08 Imquant, Inc. Stereotactic system and method for defining a tumor treatment region
EP1515158B1 (fr) * 2003-09-09 2013-07-17 Esaote S.p.A. Méthode d'imagerie à ultrasons en combinaison avec la presence d'un agent de contraste dans un objet à examiner
US20050082491A1 (en) * 2003-10-15 2005-04-21 Seppi Edward J. Multi-energy radiation detector
US7649981B2 (en) * 2003-10-15 2010-01-19 Varian Medical Systems, Inc. Multi-energy x-ray source
US7869862B2 (en) * 2003-10-15 2011-01-11 Varian Medical Systems, Inc. Systems and methods for functional imaging using contrast-enhanced multiple-energy computed tomography
US7894880B2 (en) * 2003-10-23 2011-02-22 The Board Of Trustees Of The Leland Stanford Junior University Measurement of renal extraction fraction using contrast enhanced computed tomography
JP4647360B2 (ja) * 2004-04-05 2011-03-09 富士フイルム株式会社 差分画像作成装置、差分画像作成方法、及び、そのプログラム
DE102005049586A1 (de) * 2005-10-17 2007-04-26 Siemens Ag Verfahren zur Erzeugung von CT-Darstellungen in der Röntgen-Computertomographie
US7330535B2 (en) * 2005-11-10 2008-02-12 General Electric Company X-ray flux management device
CN101074937B (zh) * 2006-05-19 2010-09-08 清华大学 能谱调制装置、识别材料的方法和设备及图像处理方法
DE102006051778A1 (de) * 2006-11-02 2008-05-15 Siemens Ag Verfahren und Einrichtung zur Anzeige eines im Rahmen einer Mammographie aufgenommenen Röntgenbildes
CN101303909B (zh) * 2007-05-11 2013-03-27 Ge医疗系统环球技术有限公司 滤波器单元,x射线管单元和x射线成像系统
DE102007034956A1 (de) * 2007-07-26 2009-02-05 Siemens Ag Verfahren zum Detektieren einer neuropathologisch veränderten Gehirnregion
US7724865B2 (en) * 2007-08-22 2010-05-25 General Electric Company System and method of optimizing a monochromatic representation of basis material decomposed CT images
BRPI0910525A2 (pt) * 2008-07-09 2015-09-29 Koninkl Philips Electronics Nv agente de contraste para a formação de imagem f19 mri e nuclear concomitantes, aparelho de diagnóstico de imagem para imagem de contraste realçado, método de diagnostico por imagem, processador programado para controlador um scanner híbrido de ressonância magnética e tomografia de emissão de pósitron, software que contém midia que pode ser lida por computador, e, aparelho de formação de imagem médica para a geração de imagens realçadas de contraste.
DK2406679T3 (da) 2009-03-11 2017-04-18 Sakura Finetek Usa Inc Autofokusfremgangsmåde og autofokusanordning
JP2011067333A (ja) * 2009-09-25 2011-04-07 Fujifilm Corp 放射線画像撮影装置及び撮影制御装置
KR101163523B1 (ko) * 2009-11-20 2012-07-06 주식회사바텍 엑스선 필터부가 구비된 엑스선 촬영장치
US10139613B2 (en) 2010-08-20 2018-11-27 Sakura Finetek U.S.A., Inc. Digital microscope and method of sensing an image of a tissue sample
US8433154B2 (en) * 2010-12-13 2013-04-30 Carestream Health, Inc. Enhanced contrast for scatter compensation in X-ray imaging
US20140323993A1 (en) * 2011-03-25 2014-10-30 Leo Pharma A/S Applicator
US9086366B2 (en) 2012-02-15 2015-07-21 L-3 Communications Security And Detection Systems, Inc. Determining a material property based on scattered radiation
DE102012217301B4 (de) * 2012-09-25 2021-10-14 Bayer Pharma Aktiengesellschaft Kombination aus Kontrastmittel und Mammographie-CT-System mit vorgegebenem Energiebereich und Verfahren zur Erzeugung tomographischer Mammographie-CT-Aufnahmen durch diese Kombination
US10296808B2 (en) 2013-03-21 2019-05-21 Koninklijke Philips N.V. Method and X-ray system for computer aided detection of structures in X-ray images
EP2987454A4 (fr) * 2013-04-16 2016-09-21 Toshiba Medical Sys Corp Tomodensitomètre à rayons x
DE102013103971A1 (de) 2013-04-19 2014-11-06 Sensovation Ag Verfahren zum Erzeugen eines aus mehreren Teilbildern zusammengesetzten Gesamtbilds eines Objekts
JP6305692B2 (ja) * 2013-05-28 2018-04-04 キヤノンメディカルシステムズ株式会社 Ｘ線診断装置
US20150036792A1 (en) * 2013-08-01 2015-02-05 Korea Advanced Institute Of Science And Technology Computed tomography apparatus, and method of generating image by using computed tomography apparatus
JP6266284B2 (ja) * 2013-09-19 2018-01-24 東芝メディカルシステムズ株式会社 Ｘ線診断装置
US10007102B2 (en) 2013-12-23 2018-06-26 Sakura Finetek U.S.A., Inc. Microscope with slide clamping assembly
US9265971B2 (en) 2014-02-07 2016-02-23 Varian Medical Systems, Inc. Systems, methods, and devices for real-time treatment verification using an electronic portal imaging device
DE102014203465A1 (de) * 2014-02-26 2015-08-27 Siemens Aktiengesellschaft Verfahren zur Auswahl eines Strahlungsformfilters und Röntgenbildgebungssystem
JP2015180859A (ja) * 2014-03-05 2015-10-15 株式会社東芝 フォトンカウンティングｃｔ装置
EP3189496A1 (fr) * 2014-09-05 2017-07-12 Koninklijke Philips N.V. Visualisation de données d'image spectrale
US9991014B1 (en) * 2014-09-23 2018-06-05 Daniel Gelbart Fast positionable X-ray filter
US9870628B2 (en) * 2015-03-18 2018-01-16 Prismatic Sensors Ab Image reconstruction based on energy-resolved image data from a photon-counting multi-bin detector
CN106353828B (zh) * 2015-07-22 2018-09-21 清华大学 在安检系统中估算被检查物体重量的方法和装置
CN107345923B (zh) * 2016-05-05 2020-05-19 清华大学 X射线探测方法、和x射线探测器
US11280803B2 (en) 2016-11-22 2022-03-22 Sakura Finetek U.S.A., Inc. Slide management system
US10806413B2 (en) 2017-04-27 2020-10-20 Medtronic Navigation, Inc. Filter system and method for imaging a subject
US10682103B2 (en) 2017-04-27 2020-06-16 Medtronic Navigation, Inc. Filter system and method for imaging a subject
US10849576B2 (en) 2017-04-27 2020-12-01 Medtronic Navigation, Inc. Filter system and method for imaging a subject
WO2018200308A1 (fr) * 2017-04-27 2018-11-01 Medtronic Navigation, Inc. Système et procédé d'imagerie d'un sujet mobile
EP3658034A1 (fr) * 2017-07-25 2020-06-03 Bayer Aktiengesellschaft Appareil pour la quantification radiopharmaceutique d'une partie corporelle
JP7169853B2 (ja) * 2018-11-09 2022-11-11 キヤノン株式会社 画像処理装置、放射線撮影装置、および画像処理方法
US10888294B2 (en) 2018-12-27 2021-01-12 Medtronic Navigation, Inc. System and method for imaging a subject
US10881371B2 (en) 2018-12-27 2021-01-05 Medtronic Navigation, Inc. System and method for imaging a subject
US11071507B2 (en) 2018-12-27 2021-07-27 Medtronic Navigation, Inc. System and method for imaging a subject
KR102202861B1 (ko) * 2019-04-09 2021-01-18 이준석 스크린 교환 장치, 이를 포함하는 생체조직 미세화 시스템, 이를 이용하는 생체조직 미세화 방법 및 이와 관련된 생체조직으로부터 타겟 물질을 분리하는 방법

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US31035A (en) * 1861-01-01 Mode op hanging covers to bailed metallic hollow ware
US38682A (en) * 1863-05-26 Improvement in fruit-presses
US2840602A (en) * 1954-01-25 1958-06-24 Sterling Drug Inc Nu-[beta-(3-amino-2, 4, 6-triiodophenyl) propionyl] amino acids, nu-acyl derivativesthereof, and process
GB1275745A (en) * 1968-06-10 1972-05-24 Nyegaard & Co As 2,4,6-triiodobenzoic acid derivatives and their use as x-ray contrast agents
NO129093B (fr) 1969-06-27 1974-02-25 Nyegaard & Co As
US4021481A (en) * 1969-06-27 1977-05-03 Nyegaard & Co. A/S Amido derivatives of 2,4,6-triiodobenzoic acids containing at least one N-hydroxyalkyl and at least two hydroxyl groups
US3894181A (en) * 1973-06-14 1975-07-08 Wisconsin Alumni Res Found Differential enhancement of periodically variable images
US3854049A (en) 1973-12-10 1974-12-10 Wisconsin Alumni Res Found Compensation for patient thickness variations in differential x-ray transmission imaging
US3974386A (en) 1974-07-12 1976-08-10 Wisconsin Alumni Research Foundation Differential X-ray method and apparatus
GB1548594A (en) 1976-06-11 1979-07-18 Nyegaard & Co As Triiodoisophthalic acid amides
US4125599A (en) * 1976-08-19 1978-11-14 Mallinckrodt, Inc. X-ray contrast agents
CH626873A5 (fr) * 1977-03-28 1981-12-15 Bracco Ind Chimica Spa
US4406878A (en) * 1978-08-02 1983-09-27 Eastman Kodak Company Iodinated contrast agent for radiography
DE2909439A1 (de) 1979-03-08 1980-09-18 Schering Ag Neue nichtionische roentgenkontrastmittel
US4243653A (en) 1979-04-27 1981-01-06 The Regents Of The University Of California Non-ionic polyiodo sugar substituted anilines
IT1193211B (it) * 1979-08-09 1988-06-15 Bracco Ind Chimica Spa Derivati dell'acido 2,4,6-triiodo-isoftalico,metodo per la loro preparazione e mezzi di contrasto che li contengono
IT1207226B (it) * 1979-08-09 1989-05-17 Bracco Ind Chimica Spa Derivati dell'acido 2,4,6-triiodo-isoftalico, metodo per la loro preparazione e mezzi di contrasto che li contengono.
US4341756A (en) * 1980-01-31 1982-07-27 The Regents Of The University Of California Novel amino-dioxepane intermediates for the synthesis of new non-ionic contrast media
NO161560C (no) * 1980-04-17 1989-09-06 Univ California Symmetriske trijodisoftaldiamid-derivater og roentgenkontrastmidler inneholdende disse.
US4766110A (en) * 1981-08-21 1988-08-23 Ryan James W Novel complex amido and imido derivatives of carboxyalkyl peptides
FR2511871A1 (fr) * 1981-08-28 1983-03-04 Guerbet Sa Procede pour augmenter la tolerance des produits opacifiants et produits opacifiants ainsi obtenus
US4455292A (en) 1982-04-05 1984-06-19 Board Of Regents, The University Of Texas System Radiological contrast composition and methods
US4716225A (en) 1984-12-27 1987-12-29 Georgetown University Radioopaque sugar derivatives and a method of metabolic mapping using the same
US5093042A (en) 1985-09-10 1992-03-03 The University Of Michigan Polyiodinated triglyceride analogs as radiologic agents
US5141739A (en) 1986-07-03 1992-08-25 Advanced Magnetics, Inc. Delivery of x-ray contrast agents using receptor mediated endocytosis
US5019368A (en) * 1989-02-23 1991-05-28 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US4861581A (en) 1986-12-05 1989-08-29 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US4887604A (en) * 1988-05-16 1989-12-19 Science Research Laboratory, Inc. Apparatus for performing dual energy medical imaging
US5043152A (en) * 1988-06-02 1991-08-27 Guerbet S.A. Novel iodinated non-ionic triiodobenzene compounds and contrast media containing them
DE69034150T2 (de) 1989-10-24 2005-08-25 Isis Pharmaceuticals, Inc., Carlsbad 2'-Modifizierte Oligonukleotide
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5198977A (en) 1990-11-27 1993-03-30 Jesse Salb System and method for localization of functional activity in the human brain
FR2687669B1 (fr) * 1992-02-24 1997-12-19 Guerbet Sa Composes utilisables dans des produits de contraste pour la radiographie.
US5299253A (en) * 1992-04-10 1994-03-29 Akzo N.V. Alignment system to overlay abdominal computer aided tomography and magnetic resonance anatomy with single photon emission tomography
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
US5408996A (en) 1993-03-25 1995-04-25 Salb; Jesse System and method for localization of malignant tissue
WO1995003428A1 (fr) 1993-07-20 1995-02-02 University Of Massachusetts Medical Center Procede d'hybridation in vivo d'acide nucleique
US5729620A (en) 1993-09-29 1998-03-17 Wang; Shih-Ping Computer-aided diagnosis system and method
US5525327A (en) * 1994-04-14 1996-06-11 Sterling Winthrop Inc. Polymeric x-ray contrast compositions containing iodinated polymeric beads and microcrystaline cellulose
US5650135A (en) * 1994-07-01 1997-07-22 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
GB9501560D0 (en) * 1995-01-26 1995-03-15 Nycomed Imaging As Contrast agents
US5796862A (en) * 1996-08-16 1998-08-18 Eastman Kodak Company Apparatus and method for identification of tissue regions in digital mammographic images
IL121084A0 (en) 1997-06-15 1997-11-20 Yeda Res & Dev Compositions and methods for diagnosis of tumors by X-ray imaging
US6751290B2 (en) * 1998-09-08 2004-06-15 Veritas Pharmaceuticals, Inc. Radiographic assessment of tissue after exposure to a compound
US6226352B1 (en) * 1998-09-08 2001-05-01 Veritas Pharmaceuticals, Inc. System and method for radiographic imaging of tissue
US6723746B2 (en) * 1998-09-08 2004-04-20 Veritas Pharmaceuticals, Inc. Functional radiographic imaging methods and agents
US20010038682A1 (en) * 1998-09-08 2001-11-08 Jesse Salb Radiographic assessment of tissue response to compounds
EP1263324B1 (fr) 2000-03-16 2009-12-02 Veritas Pharmaceuticals Evaluation radiographique de la reponse tissulaire a des composes

Also Published As

Publication number Publication date
EP1126788A2 (fr) 2001-08-29
ATE521284T1 (de) 2011-09-15
JP2002524126A (ja) 2002-08-06
AU5808599A (en) 2000-03-27
US6226352B1 (en) 2001-05-01
WO2000013590A2 (fr) 2000-03-16
US20010001011A1 (en) 2001-05-10
US6923950B2 (en) 2005-08-02
WO2000013590A3 (fr) 2000-07-20
ES2372268T3 (es) 2012-01-17
US20030091508A1 (en) 2003-05-15

Similar Documents

Publication Publication Date Title
EP1126788B1 (fr) Systeme pour l'imagerie radiographique des tissus
US6751290B2 (en) Radiographic assessment of tissue after exposure to a compound
Fredenberg Spectral and dual-energy X-ray imaging for medical applications
Smith et al. Introduction to medical imaging: physics, engineering and clinical applications
De Cecco et al. Dual energy CT (DECT) of the liver: conventional versus virtual unenhanced images
Stafford et al. Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy
US7457450B2 (en) Method for recording and evaluating image data with the aid of a tomography machine
So et al. Dual-energy CT and its potential use for quantitative myocardial CT perfusion
AU2006254747A1 (en) X-ray arrangement for the image representation of an examination object and use of the X-ray arrangement
US6723746B2 (en) Functional radiographic imaging methods and agents
US20070025514A1 (en) X-ray arrangement for graphic display of an object under examination and use of the x-ray arrangement
Mansouri et al. Dual-energy computed tomography characterization of urinary calculi: basic principles, applications and concerns
Yoshimura et al. Correlation between image noise and body weight in coronary CTA with 16-row MDCT
Bhayana et al. Material decomposition with dual-and multi-energy computed tomography
US20010038682A1 (en) Radiographic assessment of tissue response to compounds
US20040170561A1 (en) Functional radiographic imaging methods and agents
Sarnelli et al. K-edge digital subtraction imaging with dichromatic x-ray sources: SNR and dose studies
EP1263324B1 (fr) Evaluation radiographique de la reponse tissulaire a des composes
EP1263478A2 (fr) Procedes et agents d'imagerie radiographique fonctionnelle
Roberts et al. Routine oblique radiography of the pediatric lumbar spine: is it necessary?
Lee et al. Quantitative evaluation of anatomical noise in chest digital tomosynthesis, digital radiography, and computed tomography
Boyd et al. Radiation dosimetry considerations for skeletal survey imaging of multiple myeloma
Siewerdsen et al. High-performance dual-energy imaging with a flat-panel detector: imaging physics from blackboard to benchtop to bedside
Sakai et al. Effects of scan parameters on the accuracies of iodine quantification and hounsfield unit values in dual layer dual-energy head and neck computed tomography: A phantom study conducted in a hospital in Japan
Sagsoz et al. Determination of linear X-ray attenuation coefficients of pathological brain tissues and use of filters in tissue contrast enhancement in computed tomography

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010402

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20031124

17Q First examination report despatched

Effective date: 20031124

RTI1 Title (correction)

Free format text: SYSTEM FOR RADIOGRAPHIC IMAGING OF TISSUE

GRAC Information related to communication of intention to grant a patent modified

Free format text: ORIGINAL CODE: EPIDOSCIGR1

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SALB, JESSE

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 69943670

Country of ref document: DE

Effective date: 20111103

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: E. BLUM & CO. AG PATENT- UND MARKENANWAELTE VSP

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2372268

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20120117

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110824

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110824

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111226

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 521284

Country of ref document: AT

Kind code of ref document: T

Effective date: 20110824

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110824

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111125

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110824

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110824

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110824

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20120525

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 69943670

Country of ref document: DE

Effective date: 20120525

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20120827

Year of fee payment: 14

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110831

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20140227

Year of fee payment: 15

Ref country code: NL

Payment date: 20140227

Year of fee payment: 15

Ref country code: DE

Payment date: 20140228

Year of fee payment: 15

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20140227

Year of fee payment: 15

Ref country code: IT

Payment date: 20140227

Year of fee payment: 15

Ref country code: ES

Payment date: 20140227

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20140227

Year of fee payment: 15

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130831

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 69943670

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: V1

Effective date: 20150301

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20140831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140831

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150301

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140831

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140831

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 69943670

Country of ref document: DE

Effective date: 20150303

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20150430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150303

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140901

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20150925

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140901